Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response

AIMS/HYPOTHESIS: A European Phase III trial of GAD formulated with aluminium hydroxide (GAD-alum) failed to reach its primary endpoint (preservation of stimulated C-peptide secretion from baseline to 15 months in type 1 diabetes patients), but subgroup analysis showed a clinical effect when particip...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavira, Beatriz, Cheramy, Mikael, Axelsson, Stina, Åkerman, Linda, Ludvigsson, Johnny, Casas, Rosaura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487599/
https://www.ncbi.nlm.nih.gov/pubmed/28357504
http://dx.doi.org/10.1007/s00125-017-4263-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487599/
https://www.ncbi.nlm.nih.gov/pubmed/28357504
http://dx.doi.org/10.1007/s00125-017-4263-x

Ejemplares similares